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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Treatment of Acinetobacter baumannii infections is chal-
lenging owing to widespread multidrug-resistant A. baumannii (MDR-AB) and the lack of novel
agents. Although recent data suggest that levofloxacin (LVX) may have unique activity against
MDR-AB in combination with colistin (CST), further preclinical work is needed.
Methods: We used a A. baumannii type strain ATCC19606, a CST-resistant strain AB19606R, and
two clinical isolates (GN0624 and GN1115) of MDR-AB to investigate the in vitro and in vivo ef-
ficacy of LVXeCST combination. Synergy studies were performed using the microtiter plate
chequerboard assay and timeekill methodology. Inhibitory activity of antibiotics against bio-
films and the mutant prevention concentrations were also studied in vitro. A simple inverte-
brate model (Galleria mellonella) has been used to assess the in vivo activity of
antimicrobial therapies.
Results: The LVXeCST combination was bactericidal against the CST-susceptible clinical isolate
(GN0624). In checkerboard assays, synergy (defined as a fractional inhibitory concentration in-
dex of < 0.5) was observed between CST and LVX in GN0624. The combination had antibiofilm
properties on the preformed biofilms of four tested strains and could prevent the emergence of
CST-resistant A. baumanni. Treatment of G. mellonella larvae infected with lethal doses of A.
baumannii resulted in significantly enhanced survival rates when LVX was given with CST
compared with CST treatment alone (p < 0.05).of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Jixi Road Number 218,
(Y. Ye).
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j.jmii.2015.10.010Conclusion: In summary, a synergistic or additive effect between CST and LVX was observed
in vitro and in vivo against CST-susceptible A. baumannii strains, although not against CST-
resistant ones.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
During the past few decades, Acinetobacter baumannii
has become a pathogen of increased clinical importance
due to its remarkable ability to cause outbreaks of in-
fections and to acquire resistance to almost all
currently used antibiotics, including the carbapenems.
The emergence of multidrug-resistant A. baumannii
(MDR-AB) further limits the treatment options and
constitutes a serious threat to international public
health.1 The only agents that remain consistently active
in vitro against MDR-AB are the polymyxins and tigecy-
cline. However, resistance to colistin (CST) and tigecy-
cline have been increasingly reported.2,3 With very few
options now left, unorthodox combination therapies
that include CST for the treatment of infections caused
by MDR-AB are increasingly being considered, although
comprehensive clinical data are lacking.4
Levofloxacin (LVX) is one of the outstanding represen-
tatives of the third generation of quinolone antibiotics that
have been a useful class of broad-spectrum antimicrobials.
But declining susceptibilities may have implications for the
empiric use of fluoroquinolones in patients at risk of
developing infections often caused by A. baumannii.5
However, the presented study indicated that the LVXeCST
combination was shown to have activity against CST-
susceptible (CSTs), MDR clinical strains, in accordance
with a previous study.6 Although this combination appears
to be a promising treatment option, further preclinical
work is clearly needed before it can be considered for
clinical use.
Animal studies investigating new or unconventional
antimicrobial therapies are necessary in order to inform
on appropriate dosage, potential toxicity, and in vivo ef-
ficacy. However, mammalian models of infection are
associated with high cost, ethical constraints, and
specialized training requirements.7 Therefore, alternative
infection models using insects are being increasingly
employed to characterize virulence of bacterial pathogens
and to evaluate novel therapeutics prior to characteriza-
tion in mammalian models. The introduction of a Galleria
mellonella model of A. baumannii infection may prove
useful to this end. Like other nonmammalian infection
models, microbial virulence is similar in G. mellonella and
mammals, and this model has already been used to
determine the virulence of various human pathogens
including A. baumannii.8 In this study, we aimed to eval-
uate G. mellonella as a model to study the in vivo efficacy
of LVXeCST combination.ei W, et al., Activity of levofloxa
la model, Journal of MicrobiologMethods
Antibiotics
CST and LVX were commercially obtained from Sigma-
Aldrich (Shanghai, China). Stock solutions were prepared
according to the Clinical and Laboratory Standards Institute
(CLSI) guidelines in the appropriate solvent, following
which the solution was stored at 4C for up to 1 month,
conditions under which the drugs were stable.
Bacterial isolates and susceptibility testing
Isolates of A. baumannii used in this study were two
MDR-clinical isolates, CSTs strain GN0624 and CST-
resistant (CSTr) strain GN1115, as well as the A. bau-
mannii type strains ATCC 19606 and AB19606R as con-
trols. GN0624 was isolated from the urine of a
hospitalized patient who was treated in the intensive
care unit. GN1115 was isolated from the sputum of a
neurosurgical patient. Both of the two patients were
hospitalized in a tertiary-care hospital located in Anhui,
China, in 2013. GN0624 and GN1115 were identified by
API 20NE (BioMe´rieux, Marcy-l’E´toile, France) and
species-specific polymerase chain reaction for the
blaOXA-51-like gene.9 Minimum inhibitory concentrations
(MICs) of CST and LVX were obtained by the standard
agar dilution method according to CLSI recommenda-
tions. Interpretation criteria for susceptibility tests were
based on CLSI guidelines.10 Genes encoding resistance to
carbapenems (blaOXA-23-like, blaOXA-24-like, blaOXA-
51-like, blaOXA-58-like, and metallo-b-lactamase genes)
were identified with polymerase chain reaction and
sequencing as previously described.11
LVXeCST checkerboard assays
Synergy between two agents of CST and LVX was assessed
for a range of concentrations (between 0 and 8  MICs)
using the checkerboard method. In brief, 96-well microtiter
plates (Sigma-Aldrich) were set up with increasing con-
centrations of CST (0e512 mg/L) in each column and LVX
(0e1024 mg/L) in each row. Wells were inoculated with
5  105 CFU/mL of the test organism and incubated at 37C
for 18 hours.12 The fractional inhibitory concentration
index (FICI) and the susceptibility breakpoint index (SBPI)
were calculated. The FICI was interpreted as follows: syn-
ergy, FICI  0.5; antagonism, FICI > 4.0; and indifferent,cin in combination with colistin against Acinetobacter baumannii:
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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defined as a SBPI of > 2.7,13Timeekill assays
Timeekill assays were conducted for each strain using CST
alone and in combination with LVX according to a previously
described methodology.14 Drug concentrations of CST and
LVX in the following studies were adjusted to the suscep-
tible breakpoint concentration of the two drugs recom-
mended by the CLSI, i.e., CST 2mg/L, LVX 2mg/L. Tubes
containing MuellereHinton broth (MHB; Oxoid Ltd., Cam-
bridge, UK) with and without (growth control) antibiotic
were seeded with a logphase inoculum of roughly
5  105 CFU/mL to a final volume of 10 mL. Inoculated
broths were incubated in an ambient atmosphere at 37C.
Bacterial counts were measured at selected time intervals
of 0 hours, 4 hours, 8 hours, 24 hours by enumerating the
colonies in 10-fold serially diluted specimens of 100 mL al-
iquots plated on MuellereHinton agar (MHA; Oxoid Ltd.) at
37C.15 Synergism between two antimicrobials as any  2
log10 decrease of bacterial growth compared with the most
active single agent and the number of surviving organisms
in the presence of the combination must be  2 log10 CFU/
mL below the starting inoculum.12 Bactericidal activities of
drug combinations were defined as  3 log10 CFU/mL
reduction compared with the most active drug at
24 hours.16 All experiments were performed in duplicate.Biofilm formation and quantification
For this study, four A. baumannii stains mentioned above
were cultured in MHB supplemented with 0.2% glucose.
Pseudomonas aeruginosa NCTC-27853 were used as a posi-
tive control. Bacteria were enriched for 1 day at 37C in
5 mL MHB and adjusted to 0.5 McFarland standards. Cul-
tures were then diluted 1:100 in MHB supplemented with
0.2% glucose (1  106 CFU/mL) and 200 mL was added to
each well of a 96-well tissue culture-treated polystyrene
plate. Negative controls contained only MHB. After incu-
bation at 37C for 24 hours, the culture medium was
removed from each well and plates were washed twice with
phosphate-buffered saline (PBS) to remove free-floating
planktonic cells. The biofilms formed on the well bottoms
were then fixed by 100 mL methanol (100%) and incubation
for 15 minutes. After removing the methanol, the biofilm in
each plate was stained with 0.4% crystal violet (Sinopharm
Chemical Reagent Co. Ltd., Shanghai, China) solution (w/v)
for 30 minutes. The excess stain was then thoroughly rinsed
away with distilled water and the plates were air dried.
Once dry, 33% (v/v) glacial acetic acid was added to each
well. The average optical density values were calculated
for all tested strains and negative controls. These optical
density were measured at 595 nm (OD595 values) and were
considered to be a measure of the bacteria adhering to the
surface and forming biofilms. To compensate for back-
ground absorbance, OD595 readings from sterile medium,
fixative, and dye were averaged and were subtracted from
all test values.17,18Please cite this article in press as: Wei W, et al., Activity of levofloxa
In vitro and in a Galleria mellonella model, Journal of Microbiolog
j.jmii.2015.10.010Assay of the susceptibility of biofilm forming strains
to antibiotics
Biofilms of individual strains were prepared in 96-well tis-
sue culture-treated polystyrene plate. The medium in the
well was removed with aspiration and the biofilm was
treated either with CST or LVX alone or in combination. CST
and LVX alone (2 mg/L, 200 mL) or their combination
(2  2 mg/L, 200 mL) were added to bacterial cells sus-
pended in MHB supplemented with 0.2% glucose
(1  106 CFU/mL). Wells in which no test agents were added
served as controls. The medium was gently aspirated after
1 day at 37C. Inhibition of biofilm growth was quantified
using crystal violet staining as described above. A ratio of
OD value (ODr) of biofilm formation for the isolate incu-
bated with a drug to that without a drug (native biofilm)
was calculated. Lower ODr values indicate greater inhibi-
tory activity on biofilm-embedded A. baumannii. The per-
centage of biofilm inhibition was calculated using the
following equation19,20:
½1 ðOD595 of cells treated with test agent=
OD595 of untreated controlÞ  100: ð1Þ
Experiments were performed in triplicate and the data
were averaged. The results were expressed as a percentage
of biofilm inhibition.
The mutant prevention concentrations
The MPCs of the two drugs alone and in combination were
determined using a modified method described by Zhao and
Drlica21 and Zhanel et al.22 In brief, two CSTs isolates
(ATCC19606, GN0624) were grown overnight on MHA at 37C
in ambient air. The overnight growth was then swabbed into
MHB and incubated for 3 hours at 37C in ambient air in
order to achieve inocula of w1010 CFU. Samples (100 mL)
were inoculated onto MHA plates containing 0.5, 1, 2,
4, 8, 16, or 32 their CST MIC alone and in combina-
tion with LVX (2 mg/L). Finally, the inoculated plates were
incubated for 48 hours at 37C and screened visually for
growth. Each reported data point is based on at least three
independent experiments including the concentration steps
above and below the MPC. The MPC was recorded as the
lowest antimicrobial concentration at which no colonies
grew on an agar plate after 48 hours of incubation. The MIC
and MPC data were used to calculate the size of the mutant
prevention index (MPIZ MPC/MIC) for each strain and drug
combination.
G. mellonella model of A. baumannii infection
Efficacy of CST or LVX in A. baumannii infection was tested
using the G. mellonella infection model which was initially
reported by Peleg et al.23 Batches of G. mellonella (Kaide
Ruixin Co., Ltd., Tianjin, China) were stored at 4C in the
dark and were used within 10 days of receipt. Larvae were
selected to be 15e25 mm in length, having a cream color
with minimal speckling and no grey markings. Caterpillar
masses varied slightly but were typically 250 mg and this
value was used to calculate treatment doses. To establishcin in combination with colistin against Acinetobacter baumannii:
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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+ MODELthe optimal inocula required for staggered killing of G.
mellonella over 96 hours, eight caterpillars were inocu-
lated with bacterial suspensions containing final concen-
trations of 104 CFU/larva, 105 CFU/larva, and 106 CFU/
larva. A 50 mL Hamilton syringe (Hamilton, Shanghai,
China) was used to inject 10-mL aliquots of the inoculum
into the hemocoel of each caterpillar via the last left
proleg. Caterpillars were incubated at 37C and were
observed daily for 96 hours. They were considered dead if
they did not respond to touch.
Sixteen larvae of appropriate weight (0.25e0.35 g)
were randomly selected to comprise each group. Larvae
were inoculated with a lethal dose of the four strains
described above followed by tested drug 2 hours after
inoculation. Antibiotics were administered via 10 mL in-
jections into the last right proleg. Drug doses were
selected to be representative of those used to treat
human infection and consisted of CST at 2.5 mg/kg, LVX at
6.7 mg/kg. Treatment was given only once. For all ex-
periments, four control groups were used: the first group
included caterpillars that were inoculated with PBS, the
second group received the inoculum only, the third group
received antimicrobial agent(s) only, and the fourth group
included caterpillars that received no injection. If more
than one larva from these groups died, the results were
disregarded and the experiment was repeated. The cat-
erpillars were observed for survival every 24 hours for
4 days. Experiments were performed three times on
separate occasions.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism version 5.04 (GraphPad Software Inc., San Diego,
CA, USA). Survival analysis was determined using the log-
rank test, with a p value  0.05 considered statistically
significant.
Results
Genotypic and phenotypic characteristics for the
study strains
A. baumannii ATCC 19606 was susceptible to b-lactams,
aminoglycosides, quinolones, polymyxins, and tigecycline.
AB19606R was resistant to CST (MIC: > 128 mg/L) but was
susceptible to LVX (MIC Z 0.25 mg/L). GN0624 was resis-
tant to all agents tested (including carbapenems) but was
susceptible to CST (MIC Z 2 mg/L). GN1115 was resistant
to all agents tested including CST (MIC Z 16 mg/L). A.
baumannii GN0624 and GN1115 were positive for blaOXA-
51-like and blaOXA-23-like genes, whilst metallo-b-lac-
tamase genes were not detected (Table 1).
Chequerboard assays
In the chequerboard assays, no significant synergy were
observed in ATCC19606 and AB19606R as assessed using
the FICI (1.0625 and 0.5625) despite a 16-fold reduction in
the MIC of CST in the presence of subinhibitoryPlease cite this article in press as: Wei W, et al., Activity of levofloxacin in combination with colistin against Acinetobacter baumannii:
In vitro and in a Galleria mellonella model, Journal of Microbiology, Immunology and Infection (2015), http://dx.doi.org/10.1016/
j.jmii.2015.10.010
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+ MODELconcentrations of LVX. The two clinical isolates (GN0624
and GN1115) had a four-fold decrease in CST MICs and had a
reversal of LVX resistance with the change of LVX MICs from
16 mg/L to 2 mg/L and 8 mg/L, respectively. Synergistic
activity in LVXeCST combination was observed in GN0624,
which showed synergy in FICI (0.37), and in GN1115, which
showed no interaction in FICI (0.75). However, a SBPI > 2
were observed in ATCC19606, AB19606R, and GN0624,
indicative of a potent synergistic interaction (Table 1).
Timeekill assays
For the type strain ATCC19606, which was susceptible to
most antibiotics, CST and LVX showed bactericidal activity
with monotherapy. However, CST alone or in combination
reduced the initial inoculums during the 1st 8 hours in this
strain but the bactericidal effects were subsequently
abolished after 24 hours of incubation and regrowth was
detected. Both LVX alone and LVXeCST combination
expressed bactericidal activity in the strain AB19606R,
while CST alone showed no activity. A subinhibitory con-
centration of CST exhibited a rapid killing effect against
GN0624, but this was not sustained, and the isolate was
able to regrow at 24 hours to a bacterial density higher than
the starting inoculum. When two agents were combined,
however, the combination was consistently bactericidal
and no regrowth was observed after 24 hours. There was a
> 5 log10 CFU/mL difference in the viable counts compared
with cells treated with CST only at 24 hours and a 3Figure 1. Timeekill assays for colistin, levofloxacin alone, and in
ATCC19606; (B) a colistin-resistant strain AB19606R; (C) a colistin-
clinical isolate GN1115. CST Z colistin; LVX Z levofloxacin; Nil Z
Please cite this article in press as: Wei W, et al., Activity of levofloxa
In vitro and in a Galleria mellonella model, Journal of Microbiolog
j.jmii.2015.10.010log10 CFU/mL reduction compared with the starting inoc-
ulum. For the clinical isolate (GN1115), CST alone or in
combination with LVX were unable to produce bacterio-
static or bactericidal activity during the present study time
and regrowth was found at the 24th hour of incubation.
Representative timeekill curves for four isolates of A.
baumannii were shown in Figure 1. Logarithmic and fold
changes of timeekill experiments at 24 hours were pre-
sented in Table 2.
Inhibitory activity of antibiotics against biofilms
All the tested strains showed biofilm production. In the
biofilm model, susceptible breakpoint concentration of
each antimicrobial agent was used to investigate the
inhibitory effect. The use of CST as single drug treat-
ment had a very slight effect in reducing the viable CFU
of biofilm-embedded A. baumannii (GN0624). The ODr of
GN0624 was 0.931 and the percentage of biofilm inhibi-
tion was 6.9. CST alone had no effect on the other three
strains. Treatment with 2 mg/L of LVX alone had an
inhibitory effect of 3e15% on preformed biofilms of the
studied strains with the exception of ATCC19606 type
strain. However, CST plus LVX exhibited enhanced anti-
bacterial effects (ODr 0.8, 0.557, 0.223, and 0.381,
respectively) compared with the single drug therapy.
The ODr of studied strains with combined therapy
were generally lower than those used as single agent
(Table 1).combination, against: (A) Acinetobacter baumannii type strain
susceptible clinical isolate GN0624; and (D) a colistin-resistant
no antibiotic.
cin in combination with colistin against Acinetobacter baumannii:
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Table 2 Logarithmic and fold changes of time-kill experiments at 24 hours in colistinelevofloxacin combinations.
Acinetobacter
Baumannii
isolates
CST LVX CSTeLVX
LogD
(CFU/
mL)
Fold
change
Antibiotic
activity
LogD
(CFU/
mL)
Fold
change
Antibiotic
activity
Log
(CFU/
mL)
Fold
change
Antibiotic
activity
ATCC19606 1.0 10 Growth 3.5 3162 Bactericidal 0.7 5.0 Growth
AB19606R þ0.6 4.0 Growth 3.4 2511.9 Bactericidal 3.5a 3162 Bactericidal
no regrowth
GN0624 þ1.2 15.8 Growth 0.4 2.5 Growth 3.5a 3162 Bactericidal
no regrowth
GN1115 þ1.8 63.1 Growth þ0.7 5.0 Growth þ1.8 63.1 Growth
a Maximum log reduction in CFU/mL detectable by assay (standard inoculum) 5.5 log10  (lower limit of detection) 2.0 log10  0007.
CST Z colistin; LVX Z levofloxacin.
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+ MODELMPCs and MPIs calculations
The MIC and MPC data and the mutant prevention index
(MPI Z MPC/MIC) for the two CSTs strains (ATCC19606 and
GN0624) are shown in Table 3. The MPCs of CST were very
high in the two tested strains (MPCs > 128 mg/L) with CST
monotherapy. When 2 mg/L LVX was used in combination
with CST; however, a decrease in MPCs of CST could be
found (MPCs 16mg/L and 16 mg/L, respectively). Besides,
the MPI for CST tested alone was at least 128 for the two
isolates. When CST was combined with LVX, nevertheless,
the CST MPIs decreased > eight-fold and > 16-fold for the
strains of ATCC19606 and GN0624, respectively.Activities of CST and LVX in the G. mellonella
infection model
With the live bacterial inocula, larval survival was
affected by the inoculum dose and larger doses of bacteria
gave reduced larval survival in a dose-dependent manner
during a 96-hour incubation. Kinetics of four tested strains
at various numbers of CFU/mL in G. mellonella over
96 hours are shown in Figure 2. No macroscopic changes or
deaths were observed in the untreated group (PBS only),
uninfected group (antimicrobial agents only), and non-
injection group. Most of the killing occurred in the first
24 hours, followed by further killing in the subsequent
3 days. The optimal inoculum able to promote staggered
killing of 80% of larvae over 96 hours for use in treatmentTable 3 Minimum inhibitory concentrations, mutant preventio
alone and in combination with levofloxacin.
Acinetobacter baumannii isolate MICs (mg/L)
CST CST þ LVXa
ATCC 19606 0.5 0.03125
GN0654 2 0.5
a MIC of colistin in combination with levofloxacin.
b MPC of colistin in combination with 2 mg/L levofloxacin.
c MPI colistin in combination with levofloxacin.
CSTZ colistin; LVXZ levofloxacin; MPI (MPC/MIC)Z mutant prevent
concentrations).
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j.jmii.2015.10.010assays varied from 105 CFU/larval to 106 CFU/larval. In the
study, CST monotherapy protected G. mellonella from A.
baumannii ATCC19606-mediated killing but performed
poorly against the other three strains. LVX had a weak
effect in treating the strains of A. baumannii ATCC19606
and AB19606R infections, as would be predicted from the
in vitro susceptibility data. For the clinical strains, how-
ever, LVX had no effect on larval survival compared with
the PBS-treated controls. Treatment with CST-LVX resul-
ted in survival of 75%, 37.5%, 87.5%, and 37.5% of
ATCC19606-, AB19606R-, GN0624-, and GN1115-infected
larvae (Figures 3AeD), respectively. The combination
was significantly more effective (p < 0.05) than CST
monotherapy against the CSTs clinical isolates(GN0624)
studied in vivo.Discussion
Current treatment options for infections caused by A.
baumannii are severely limited. CST (polymyxin E deriva-
tive), a previously abandoned polymyxin antibiotic, has
re-emerged as a last-resort therapeutic option. CST in
both parenteral and aerolized administration is, nowa-
days, the treatment of choice for infections by these
species. However, CST administration alone is also asso-
ciated with significant nephrotoxicity and hetero-
resistance to CST and is increasingly reported in both type
strains and clinical isolates.2,24 The erosion of effective
treatments by resistance, combined with a drugn concentrations, and mutant prevention index for colistin
MPCs (mg/L) MPIs (MPC/MIC)
CST CST þ LVXb CST CST þ LVXc
>128 16 >256 32
>256 16 >128 8
ion index (mutant prevention concentrations/minimum inhibitory
cin in combination with colistin against Acinetobacter baumannii:
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Figure 2. Kill kinetics of strains: (A) ATCC19606; (B) AB19606R; (C) GN0624; and (D) GN1115 at various numbers of CFU/mL in
Galleria mellonella over 96 hours. Curves were plotted from single experiments using eight insect larvae. PBS Z phosphate-
buffered saline.
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terest in using unorthodox combination therapies for A.
baumannii infections.12Figure 3. Survival curves for Galleria mellonella larvae inoculat
(B) a colistin-resistant A. baumannii strain (AB19606R); (C) two clin
colistin (2.5 mg/kg), levofloxacin (6.7 mg/kg), or a levofloxacinec
ment. CST Z colistin; LVX Z levofloxacin; PBS Z phosphate-buffe
Please cite this article in press as: Wei W, et al., Activity of levofloxa
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j.jmii.2015.10.010The bactericidal effect of several major types of anti-
biotics has recently been demonstrated to be dependent on
the formation of toxic amounts of hydroxyl radicals (OH	)ed with: (A) Acinetobacter baumannii type strain ATCC 19606;
ical strains GN0624; and (D) GN1115 following treatment with
olistin combination. Data from a single representative experi-
red saline.
cin in combination with colistin against Acinetobacter baumannii:
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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However, bactericidal activity of CST does not follow the
common OH	-mediated killing discovered in major groups
of bactericidal antibiotics, including quinolones.25 More-
over, combination of CST and ciprofloxacin (fluo-
roquinolones) has been used with clinical success for
decades at the Copenhagen CF Center for preventing and
postponing chronic P. aeruginos infection.26 As we know,
fluoroquinolones exhibit concentration-dependent killing
and a postantibiotic effect. Based on these data, we focus
on LVX which is another outstanding representative of the
third generation of quinolone antibiotics. LVX has been a
useful broad-spectrum antimicrobial in the past few de-
cades, whereas the efficacy of this agent may be now
fading. Therefore, we looked at the effects of combining
the CST with LVX against A. baumannii in this study.
In the current study, LVX lacked in vitro activity as a
single agent against the two clinical isolates. Nevertheless,
we confirmed that the combination of CST and LVX exhibi-
ted enhanced in vitro and in vivo activity against the CSTs
clinical isolate, in accordance with the previous results
reported by Safarika et al.6 The bactericidal activity of CST
is partly due to its detergent effect on the bacterial cell
membrane. This disruptive effect on membrane integrity
may account for the in vitro synergy observed with LVX.27
The presented results of chequerboard assays provide evi-
dence that CST possess a considerable synergy with LVX
against CSTs A. baumannii. The efficacy of the interaction
with LVX is greater as the MIC levels of CST and LVX
decrease. The SBPI is a novel parameter that relates the
magnitude of the interaction to the pharmacodynamic
breakpoints used to determine susceptibility in vivo. A SBPI
of > 2 indicates that the agents are more active in com-
bination than when used alone.13 In timeekill assays, the
clinical isolate (CSTs) did not display sustained bactericidal
activity at susceptible breakpoint concentration with CST
monotherapy due to its heteroresistance as described
previously.28 When combined with LVX, however, the drugs
were not only synergistic but also bactericidal and pre-
vented the regrowth of CSTs bacteria. Furthermore, the
concentrations of CST required to mediate LVX synergy
in vitro are relatively low, which may reduce the risk of
developing renal impairment if the agents are given
together. Yet despite all that, this combination had poor
antibiotic activities on the CSTr strains.
A. baumannii has the ability to form biofilms, which may
play a role in the process of colonization. The ability to
adhere to and form biofilms on the surface of inanimate
objects might be the cause of its strong ability to survive in
hospital environments.29 Low O2 availability is a common
condition in infectious biofilm. As far as we know, bacte-
ricidal drugs such as CST with OH	-independent killing have
a better effect on anaerobically compared with aerobically
grown cells. Therefore, antimicrobial peptides may be
useful for the treatment of Gram-negative bacteria growing
at low oxygen tension.26 However, CST monotherapy
seemed unlikely to make much effect in our study. How-
ever, the synergistic effect of LVXeCST combination ther-
apy was observed both in CSTs and CSTr strains. The results
indicated that the LVXeCST combination had beneficial
effect in vitro biofilm infections.Please cite this article in press as: Wei W, et al., Activity of levofloxa
In vitro and in a Galleria mellonella model, Journal of Microbiolog
j.jmii.2015.10.010Besides simply focusing on enhancing the activity of
bacterial killing, evaluation of combination therapy on
resistance inhibiting is also extremely important as drug-
resistant strains are emerging so rapidly. The problem of
antibiotic resistance is likely to get worse, in part because
the therapeutic concentrations currently used, which block
growth of the majority of the susceptible pathogens, are
often the very concentrations required to selectively enrich
the resistant mutant portion of the population.30 In our
experiment, although the MICs of CST to ATCC19606 and
GN0624 were low, the MPCs of this agent were high. The
high MPC values in our study suggest the possibility of
enriching CST resistant mutant subpopulations during
treatment with CST monotherapy. Zhao and Drlica21
showed that with antibiotics individually having high
MPCs, combination therapy provided a feasible method to
curb the emergence of resistance. Combination therapy
using two drugs acting with different antimicrobial mech-
anisms would require susceptible bacteria to acquire two
concurrent mutations for growth. Our experimental results
demonstrated that combinations of CST and LVX could
prevent the emergence of CSTr A. baumanni, which was
consistent with the previous results reported by Cai et al.31
The use of G. mellonella as a model to elucidate the
pathogenicity of microorganisms has been widely re-
ported.32 It shares many of the advantages of mammalian
models while being free of the ethical and logistical
constraints that accompany their use. In vitro data on the
potential for CST-LVX regimens to be beneficial in treat-
ment were correlated by the in vivo studies using G.
mellonella larvae. In Galleria organisms, CST and LVX
given together at humanized doses significantly improved
survival against infections with A. baumannii. The main
consideration of using the minimum administered dose for
CST is to reduce its nephrotoxicity. Our in vivo model
demonstrated improvement with addition of CST (2.5 mg/
kg) to LVX (6.7 mg/kg). The precise mechanisms of the
synergy of bacterial killing and suppression of resistance
for CST and second antibiotics are largely unknown but
might result from immunomodulatory activities of the
compound. Whether this phenomenon is species-specific
and has any implications for the selection of fluo-
roquinolones for use in unorthodox combinations to treat
human infections is unknown and requires further
investigation.
In summary, a synergistic or additive effect between CST
and LVX was observed in vitro and in vivo against CSTs A.
baumannii strains, although not against CSTr ones. How-
ever, our results should be considered with care for several
reasons. A limitation of this study is the use of limited
isolates. In addition, we cannot conclude that our in vitro
results will hold true with treatment durations longer than
72 hours. Besides, for LVXeCST combination therapy to be
employed effectively and safely, further work on the
pharmacokinetic parameters of this combination in vivo
will be needed. Moreover, studies employing mammalian
models that seek to assess the activity of CST combinations
in vivo versus Gram-negative pathogens are now war-
ranted. Finally, confirmation of these results in clinical
studies is needed before these regimens can be adopted for
use in the care of patients.cin in combination with colistin against Acinetobacter baumannii:
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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